Mente

Neurotech International Limited is a medical device and solutions company incorporated in Australia and operating through its wholly-owned, Malta-based subsidiary AAT Research Limited. Neurotech’s primary mission is to improve the lives of people with neurological conditions, with a vision of becoming the global leader in home-use and clinical neurotechnology solutions that are both accessible and affordable. Mente is the world’s first home therapy that is clinically proven to improve relaxation in autistic children with elevated Delta band brain activity. Mente is a recognised pioneer and market leader in this field. Our product has won numerous international awards including the World Intellectual Property Organisation Award for Innovative Enterprises, 1st Prize in the Malta Innovation Awards, Malta eBusiness Best Application Award and we were ‘Highly Commended’ in the 2020 Celebrating Neurodiversity Awards for Assistive Technology Implementation. Mr Griffiths is a member of the Board of Directors of Lavastorm Analytics and the Board of Trustees of the Anita Borg Institute and also acts as an Investment Board Advisor to Ottawa-based Mistral Ventures and New York-based Bridge Growth Capital. Dr Cantor is a Fellow with the National Academy of Neuropsychology, former President of the EEG and Clinical Neuroscience Society, President of the International Society of Neurofeedback and Research and is Board Certified in Quantitative EEG and Board Certified in Neurofeedback. Dr Evian Gordon is the Executive Chairman of Brain Resource.